<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738777</url>
  </required_header>
  <id_info>
    <org_study_id>N08AFT</org_study_id>
    <secondary_id>EudraCT; 2008-000644-13</secondary_id>
    <nct_id>NCT00738777</nct_id>
  </id_info>
  <brief_title>Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer</brief_title>
  <official_title>A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate prospectively whether short term endocrine treatment can induce molecular
      changes, predictive for therapy response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform a randomized, open-label, single-institution study. It will compare the
      efficacy of three different endocrine treatment regimens (Anastrozole +/- Fulvestrant or
      Tamoxifen) in changing proliferation-index and inducing apoptosis during a 2-6 week
      pre-operative treatment period in breast cancer patients. These results will be correlated to
      gene expression profiles, phosphorylation status of the ER, SNPs in CYP450 sequences,
      tamoxifen metabolite concentrations, changes in estrogen serum levels and protein expression
      patterns.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2008</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in tumor cell proliferation and induced apoptosis.</measure>
    <time_frame>At baseline and after 2-6 weeks of endocrine treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in gene expression after different endocrine treatment exposures</measure>
    <time_frame>At baseline and after endocrine treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole + Fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tamoxifen (pre-menopausal and male patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg,QD,PO</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole+Fulvestrant</intervention_name>
    <description>Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with proven invasive adenocarcinoma of the breast

          -  Any tumor with a size â‰¥ 1cm (NOT inflammatory breast cancer)

          -  WHO-performance score 0 or 1

          -  Written informed consent

        Exclusion Criteria:

          -  Clues of metastatic disease by clinical examination according to most recent NABON
             guidelines

          -  Multicentric breast cancer

          -  Inflammatory breast cancer

          -  Hormone replacement during the last 12 months

          -  Other systemic treatment during the waiting time till surgery

          -  Already planned date for surgery within the next 2 weeks

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering adequate informed consent or compliance with the study protocol

          -  Patient's refusal to undergo a core biopsy procedure of the primary tumor before the
             start of treatment

        NB: a concomitant malignancy within the last five years is not an exclusion criterium,
        because survival is not the primary endpoint. Just as prior invasive breast cancer or DCIS
        within the last 15 years is not an exclusion criterium.

        NB: Patients of childbearing potential must implement adequate non-hormonal contraceptive
        measures during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine C Linn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine C Linn, MD</last_name>
    <phone>+31-20-5129111</phone>
    <phone_ext>2591</phone_ext>
    <email>s.linn@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rutger HT Koornstra, MD</last_name>
    <phone>+31-20-5129111</phone>
    <phone_ext>6900</phone_ext>
    <email>r.koornstra@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>den Haag</city>
        <state>ZH</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H M Oosterkamp, MD</last_name>
    </contact>
    <investigator>
      <last_name>H M Oosterkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine C Linn, MD</last_name>
      <phone>+31-20-5129111</phone>
      <phone_ext>2591</phone_ext>
      <email>s.linn@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Annelot van Rossum, MD</last_name>
      <phone>+31-20-5129111</phone>
      <phone_ext>2004</phone_ext>
      <email>a.v.rossum@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine C Linn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul C de Jong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul C de Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanneke WM Laarhoven, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hanneke WM Laarhoven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-operative</keyword>
  <keyword>endocrine treatment</keyword>
  <keyword>drug resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

